Clinical Trial Update: Add-on Aripiprazole on Cardiometabolic Profile in Treatment Resistant Schizophrenia: RCT [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating add-on aripiprazole and its effect on cardiometabolic risk in treatment-resistant schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia
• Treatment-resistant Schizophrenia

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

Sponsor: All India Institute of Medical Sciences, Bhubaneswar | Conditions: Difference in the Change in Cardiovascular Risk in Treatment Resistant Schizophrenia | Phase 4 | Status: UNKNOWN